Pharmaceutical

Incyte acquires global rights to MorphoSys’ tafasitamab

Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through an asset purchase agreement with MorphoSys.

Feb 6, 2024 - 18:00
Incyte acquires global rights to MorphoSys’ tafasitamab
Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through an asset purchase agreement with MorphoSys.
Read the original article

Tags:

Previous Article

Silence announces $120m private placement for depositary shares

Next Article

Risk adjusted net present value: What is the current valuation of Caribou Biosci...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biotechs face challenges as the industry’s annual bash returns to Boston

STAT+: Biotechs face challenges as the industry’s annua...

Jun 4, 2023

Grifols gears up for FDA approval of fibrinogen replacement therapy

Grifols gears up for FDA approval of fibrinogen replace...

Feb 14, 2024

Indena’s CDMO services: Full manufacturing capabilities for pharma ingredients

Indena’s CDMO services: Full manufacturing capabilities...

Mar 13, 2024